This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Healthways Reports Fourth-Quarter Revenues Of $175.2 Million

Ben R. Leedle, Jr., president and chief executive officer of Healthways, Inc. (NASDAQ: HWAY), today announced financial results for the fourth quarter and year ended December 31, 2012. For the fourth quarter, total revenues were $175.2 million compared with $180.0 million for the fourth quarter of 2011. Net income per diluted share for the fourth quarter of 2012 was $0.02 compared with a loss for the fourth quarter of 2011 of $5.32. Excluding a restructuring charge of $0.03 per diluted share for capacity realignment costs, adjusted net income per diluted share for the fourth quarter of 2012 was $0.05. For the fourth quarter of 2011, adjusted net income per diluted share was $0.27, excluding restructuring charges related to severance costs and Cigna-dedicated capacity reductions and impairment charges related to the write down of goodwill.

Total revenues for 2012 were $677.2 million compared with $688.8 million for 2011. Net income per diluted share for 2012 was $0.24 compared with a net loss per diluted share for 2011 of $4.68. Excluding the restructuring and impairment charges discussed above, adjusted net income per diluted share was $0.27 for 2012 compared with $0.85 for 2011.


See pages 8-9 for a reconciliation of GAAP and non-GAAP measures

3 Months Ended

12 Months Ended

December 31,

December 31,


2011 (1)


2011 (1)

Domestic, excluding restructuring and impairment charges
$ 0.00 $ 0.31 $ 0.26 $ 0.98
International, excluding restructuring charges   0.05     (0.04 )   0.01     (0.13 )
Adjusted net income per diluted share 0.05 0.27 0.27 0.85
Restructuring charges (2) (0.03 ) (0.17 ) (0.03 ) (0.16 )
Impairment charges (2)   -     (5.43 )   -     (5.36 )
Net income (loss) per diluted share (3) $ 0.02 $ (5.32 ) $ 0.24 $ (4.68 )

(1) The assumed exercise of stock-based compensation awards for the three and twelve months ended December 31, 2011 was not considered because the impact would be anti-dilutive.

(2) Per-share results differ for the three and twelve months ended December 31, 2011 due to different weighted average outstanding shares and equivalents for each period.

(3) Figures may not add due to rounding.

Leedle remarked, “Healthways’ financial and operating performance for the fourth quarter and the year was on track strategically, tactically and financially with our plans to return the Company to a path of consistent profitable growth. Because of the strong business development success we achieved during 2012, we have strong visibility to a return to revenue growth in 2013 and beyond. We are also confident that the ramping of our existing contract base during 2013, along with expected new and renewed contracts signed in 2013, will provide for a full return to sustainable profitable growth for 2014 and beyond.”

1 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.14 -0.11%
FB $117.67 -0.12%
GOOG $703.43 0.29%
TSLA $213.00 0.69%
YHOO $36.96 0.05%


Chart of I:DJI
DOW 17,667.39 +6.68 0.04%
S&P 500 2,049.06 -1.57 -0.08%
NASDAQ 4,707.9250 -9.1690 -0.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs